Urology Practice Publishes Study Showing Oncotype DX® Increases Use of Active Surveillance in Prostate Cancer Patients by 56 Percent

Press Releases

<< Back
July 30, 2015 at 8:00 AM EDT

Urology Practice Publishes Study Showing Oncotype DX® Increases Use of Active Surveillance in Prostate Cancer Patients by 56 Percent

REDWOOD CITY, Calif., July 30, 2015 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Urology Practice published results from the second clinical utility study of the Oncotype DX® prostate cancer test, showing that incorporation of the test's Genomic Prostate Score (GPS) in treatment planning resulted in greater recommendations and acceptance of active surveillance as initial management of prostate cancer in low and low-intermediate risk patients. 

"Despite increasing awareness of active surveillance as a viable alternative to immediate intervention in men with clinically low-risk prostate cancer, its adoption has been limited largely due to physician and patient concerns around the accuracy of disease risk assessment," said Marc Dall'Era, M.D., principal investigator of the study and vice chair of Urology at the University of California, Davis Comprehensive Cancer Center. "Our study showed that incorporation of the Oncotype DX results into clinical practice significantly increased the number of patients who chose active surveillance and avoided the adverse impact on quality of life that can result from invasive treatments, as well as their associated costs."    

The multi-center study included 211 patients from 10 sites across the United States. The review of patient charts showed a relative increase of 56 percent in use of active surveillance in patients who received their Oncotype DX GPS compared to patients from the same practices with similar risk factors who were not tested.

Additionally, the results showed an increase in physician recommendation of active surveillance that was consistent with a previous prospective clinical study published earlier this year. Together, the two published clinical utility studies demonstrate that use of Oncotype DX changes both treatment recommendations and actual treatment received, resulting in greater recommendation and adoption of active surveillance.

"These data from actual patient charts add an important real-life perspective on the value of our test," said Phil Febbo, M.D., chief medical officer, Genomic Health. "Combined with 14 studies including more than 2,000 patients and a recent favorable draft local coverage determination on Medicare coverage, we believe this publication further supports our efforts to secure reimbursement for the Oncotype DX prostate cancer test."

About Oncotype DX Prostate Cancer Test
The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The Oncotype DX prostate cancer test identifies which clinically low-risk patients are eligible for active surveillance, as well as those who may benefit from immediate treatment by predicting disease aggressiveness. With half a million patients tested in more than 90 countries, Oncotype DX testing has redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about the Oncotype DX prostate cancer test, visit: www.OncotypeDX.com or www.myprostatecancertreatment.org.

About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from diagnosis to treatment selection and monitoring. The company is based in  Redwood City, California, with European headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of the test to physicians, patients and payors. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the ability of test results to change treatment decisions; the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's quarterly report on Form 10-Q for the year ended March 31, 2015. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

Genomic Health, Inc. logo.

Logo - http://photos.prnewswire.com/prnh/20130425/SF01493LOGO


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/urology-practice-publishes-study-showing-oncotype-dx-increases-use-of-active-surveillance-in-prostate-cancer-patients-by-56-percent-300121019.html

SOURCE Genomic Health, Inc.

News Provided by Acquire Media